Lupin Ltd’s US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has launched the generic fenofibric acid delayed release capsules in 45 mg and 135 mg strengths.
These are the generic equivalent of AbbVie Inc.’s Trilipix indicated as co‐administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.
Trilipix delayed release capsules had yearly sales of around $449.5 million in the US, Lupin said in its filings with the stock exchanges.
The Lupin stock was up by Rs 11.40 to Rs 866.80 on the BSE.